AO GENERIUM
29
3
7
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
3.4%
1 terminated/withdrawn out of 29 trials
95.2%
+8.7% vs industry average
45%
13 trials in Phase 3/4
0%
0 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
Role: lead
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Role: lead
An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease
Role: lead
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
Role: lead
A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers
Role: lead
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
Role: lead
A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers
Role: lead
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
Role: lead
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
Role: lead
A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers
Role: lead
A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers
Role: lead
A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers
Role: lead
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
Role: lead
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
Role: lead
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
Role: lead
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
Role: lead
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
Role: lead
Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
Role: lead
Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®
Role: lead
Observational Study of Elizaria® in aHUS Patients
Role: lead